Related Experiment Video

Updated: Mar 20, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

985

Systematic Review of Relapsed or Refractory Mantle Cell Lymphoma (MCL) Clinical Trials: Implications for Decision

S Sorensen1, E Dorman1, Y Xu2

  • 1Evidera, Bethesda, MD, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 21, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

820

Related Experiment Videos

Last Updated: Mar 20, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

985
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

820

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

Articles linked to this work by shared authors, journal, and citation graph.

[Effect of hsdS homologous gene duplication on pathogenicity-related phenotypes and gene expression in Mycoplasma pneumoniae].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026

Dietary hydrolysed tannins regulate carcass performance and meat traits in Hu sheep through microbial regulation.

Animal : an international journal of animal bioscience·2026

Third-Order Nonlinear Hall Effect in Altermagnet RuO_{2}.

Physical review letters·2025

Breast tumour classification in DCE-MRI via cross-attention and discriminant correlation analysis enhanced feature fusion.

Clinical radiology·2025

Efficient Spin-to-Charge Conversion via Altermagnetic Spin Splitting Effect in Antiferromagnet RuO_{2}.

Physical review letters·2023

[Clinical features of IgG4-related lung disease].

Zhonghua yi xue za zhi·2023

Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole-Genome Sequencing in Advanced Non-small-Cell Lung Cancer.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Does conventional cost-effectiveness analysis disadvantage treatments for severe disease? Evidence from U.S. value assessments.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Incorporating Equity Considerations Related to Financial Protection Through Extended Cost-Effectiveness Analysis: A Systematic Review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

How Long Should We Wait? The Impact of Immature Data on Colorectal Cancer Decision Modeling.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

What Age is Appropriate for Self-Reporting EQ-5D-Y-3L? Chinese Insights from a Sample of Children Aged 6-11 years.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us